CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
auranofin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02063698
NCT02063698Phase 2Completed
CompareCT.gov

A Pilot Randomized, Placebo-Controlled Study to Test Auranofin (Ridaura®) to Control the Paclitaxel-Induced Pain Syndrome (PIAPS)

Mayo Clinic·interventional·Posted Feb 14, 2014·Updated Apr 23, 2019

In Brief

A Phase 2 clinical trial evaluating auranofin, placebo, and 1 other intervention for Pain. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This randomized pilot clinical trial studies whether auranofin will relieve pain following paclitaxel in patients who have previously experienced paclitaxel-induced pain. Auranofin is a drug given by mouth to treat other diseases such as rheumatoid arthritis, and is being studied to see if it will decrease pain following paclitaxel.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 14, 2014
Enrollment StartFeb 19, 2014
Primary CompletionNov 11, 2015
Study CompletionNov 11, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 12.4 years ago

Interventions

auranofindrug

Given PO

placeboother

Given PO

questionnaire administrationother

Ancillary studies